BriaCell Therapeutics (NASDAQ:BCTX) Given Buy Rating at HC Wainwright

BriaCell Therapeutics (NASDAQ:BCTX)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a report released on Thursday, Benzinga reports. They currently have a $15.00 target price on the stock. HC Wainwright also issued estimates for BriaCell Therapeutics’ Q1 2025 earnings at ($0.30) EPS, Q2 2025 earnings at ($0.21) EPS, Q3 2025 earnings at ($0.19) EPS and Q4 2025 earnings at ($0.17) EPS.

BriaCell Therapeutics Trading Up 2.5 %

Shares of BriaCell Therapeutics stock opened at $0.98 on Thursday. BriaCell Therapeutics has a 52 week low of $0.46 and a 52 week high of $6.16. The company’s 50-day moving average price is $0.70 and its two-hundred day moving average price is $1.39. The stock has a market cap of $18.00 million, a PE ratio of -0.79 and a beta of 1.34.

Institutional Trading of BriaCell Therapeutics

A hedge fund recently raised its stake in BriaCell Therapeutics stock. Onyx Bridge Wealth Group LLC lifted its stake in shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX) by 66.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 50,000 shares of the company’s stock after acquiring an additional 20,000 shares during the quarter. Onyx Bridge Wealth Group LLC owned 0.31% of BriaCell Therapeutics worth $143,000 at the end of the most recent reporting period. 15.42% of the stock is owned by institutional investors and hedge funds.

About BriaCell Therapeutics

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.